NCT06785090CompletedPhase 4
Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
Source: ClinicalTrials.gov · Last updated 6 May 2025
Brief summary (registry, in English)
The goal of this clinical trial is to learn if bromfenac ophthalmic solution can prevent cystoid macular edema (CME) and reduce macular thickness in patients undergoing phacoemulsification surgery for cataract removal. The main questions it aims to answer are: Does bromfenac reduce the incidence of CME after cataract surgery? Does bromfenac effectively control macular thickness postoperatively compared to standard care? investigators will compare the effects of bromfenac ophthalmic solution to a control group receiving standard postoperative treatment to see if bromfenac provides additional benefits. Participants will: Use bromfenac ophthalmic solution as prescribed postoperatively. Attend follow-up visits for macular thickness measurements and assessments of eye health. Undergo routine postoperative evaluations to monitor for adverse effects.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 87 (actual)
- First submitted
- 15 Jan 2025
- Start date
- 1 May 2023
- Primary completion date
- 31 Jan 2024
- Lead sponsor
- Inas Abd
- NCT number
- NCT06785090
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 87
- From 1 May 2023 to the primary completion date, 31 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have undergone previous ocular surgery in the same eye, such as:
- Retinal laser therapy
- Corneal surgery
- Patients who developed severe adverse effects from other drugs or had complications intraoperatively or postoperatively unrelated to bromfenac.
- Patients taking antiglaucoma medications.
Other illness
- Patients with glaucoma, ocular hypertension, pseudo-exfoliation syndrome, or any optic nerve disease.
- Patients with ocular diseases that might influence macular thickness, such as:
- History of uveitis
- Patients with an allergy to one of the postoperative medications.
Age
- Patients less than 18 years of age.
- Age-related macular degeneration
Other
- Epiretinal membrane
- Intraoperative complications
- Traumatic cases
- Vitrectomy
- Intravitreal injection
- Patients lost to follow-up.
Who the study is looking for
- All patients 18 years of age and older.
- Patients diagnosed with cataracts.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| College of Medicine, University of Baghdad Coordinator of this site? Confirm its status | Baghdad | Iraq | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.